{
    "id": 29834,
    "fullName": "MDK - ERBB2",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MDK-ERBB2 results from the fusion of MDK and ERBB2 (HER2), which leads to activation of Erbb2 (Her2) and downstream signaling and is transforming in cell culture (PMID: 25889497). MDK-ERBB2 has been identified in gastric cancer (PMID: 25889497).",
            "references": [
                {
                    "id": 14901,
                    "pubMedId": 25889497,
                    "title": "Oncogenic HER2 fusions in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889497"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4192,
        "geneSymbol": "MDK",
        "terms": [
            "MDK",
            "ARAP",
            "MK",
            "NEGF2"
        ]
    },
    "variant": "MDK - ERBB2",
    "createDate": "04/24/2019",
    "updateDate": "09/25/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2064,
                "geneSymbol": "ERBB2",
                "terms": [
                    "ERBB2",
                    "CD340",
                    "HER-2",
                    "HER-2/neu",
                    "HER2",
                    "MLN 19",
                    "NEU",
                    "NGL",
                    "TKR1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 16776,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (ado-trastuzumab emtansine) inhibited growth of transformed cells expressing MDK-ERBB2 in culture and inhibited tumor growth in xenograft models (PMID: 25889497).",
            "molecularProfile": {
                "id": 31929,
                "profileName": "MDK - ERBB2"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14901,
                    "pubMedId": 25889497,
                    "title": "Oncogenic HER2 fusions in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31929,
            "profileName": "MDK - ERBB2",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}